Far from the quiet of ordinary days, a virus that the world has few tools to answer has pushed the Democratic Republic of Congo past ten thousand recorded cases and nearly five thousand deaths since mid-May. It is the Bundibugyo strain, for which no approved vaccine or specific treatment yet exists, and its reach now extends beyond Congo's borders into Kenya and Nigeria. The story is one of human vulnerability meeting the limits of present knowledge, where the fate of many depends on trials still unfolding.
DR Congo Ebola Cases Pass 10,000 as Bundibugyo Outbreak Spreads Abroad Without Approved Vaccine
At least 4,887 people have died and 10,060 cases have been reported in DR Congo, with nine infections and two deaths confirmed in Kenya.
No approved vaccine and no specific treatment for the virus now spreading
Mark
Ten thousand cases and nearly 4,900 deaths. Why does this one feel different from earlier Ebola outbreaks?
Mimi
Mostly because of the virus. It's Bundibugyo, and there's no approved vaccine or specific treatment for it. The Africa CDC calls it the fastest-growing Ebola outbreak in history.
Luke
That's the Africa CDC's characterization, worth saying plainly. The case and death counts come from Congolese health authorities, and the reporting doesn't say how those were compiled.
Mark
And it has crossed borders?
Mimi
Kenya has confirmed nine infections, two of them fatal, traced to a patient who traveled from Congo through Uganda to Nairobi. Nigeria confirmed a case in a Swiss woman who had visited Uganda.
Luke
Her case is unresolved. Authorities are still investigating where she caught it, so we shouldn't assume the route.
Mark
Why is it hard to stop?
Mimi
It spreads through blood and other bodily fluids, and early symptoms can resemble malaria, so isolation can come late.
Mark
Is anything being tested?
Mimi
Two antiviral approaches have been in trials since July, and two more trials are testing the Ervebo vaccine against Bundibugyo.
Luke
Testing isn't results. Ervebo is approved only for Ebola virus, and nothing here says any trial has shown it works against this strain.
The Pulse
- Ten thousand cases and nearly five thousand deaths have accumulated in Congo since the outbreak was identified in mid-May.
- Responders have no approved vaccine or specific treatment for Bundibugyo, leaving them without the usual tools to protect contacts or heal the sick.
- Early symptoms resembling malaria risk delaying isolation, letting infectious patients move unnoticed through communities.
- The virus has crossed borders, with nine infections and two deaths in Kenya and a confirmed case in Nigeria under investigation.
- Two antiviral trials running since July and two Ervebo trials against Bundibugyo are the best hope for a way forward.
Far from the quiet of ordinary days, a virus that the world has few tools to answer has pushed the Democratic Republic of Congo past ten thousand recorded cases and nearly five thousand deaths since mid-May. It is the Bundibugyo strain, for which no approved vaccine or specific treatment yet exists, and its reach now extends beyond Congo's borders into Kenya and Nigeria. The story is one of human vulnerability meeting the limits of present knowledge, where the fate of many depends on trials still unfolding.
Health authorities in the Democratic Republic of Congo now count 10,060 Ebola cases and 4,887 deaths since the outbreak was identified in mid-May. The Bundibugyo virus driving this toll has no approved vaccine and no specific treatment, and the Africa Centres for Disease Control and Prevention has described it as the fastest-growing Ebola outbreak in history.
The disease has already moved beyond Congo. Kenya has confirmed nine infections, including two deaths, after a patient travelled from Congo through Uganda to Nairobi. In Nigeria, a Swiss woman who fell ill after visiting Uganda tested positive; she has been evacuated to Switzerland while investigators work to determine where she was infected.
Ebola spreads through contact with infected blood and bodily fluids, and its early signs can resemble malaria, which can delay isolation. With no tools tailored to this strain, responders are working with little more than vigilance.
Research is underway. Two antiviral approaches have been in clinical trials since July, and two more trials are testing whether the Ervebo vaccine, approved only for Ebola virus, can protect against Bundibugyo. Their results, along with the course of cases in Kenya, will shape what comes next.
Health authorities in the Democratic Republic of Congo now count 10,060 Ebola cases and 4,887 deaths since the outbreak was identified in mid-May. The figures put the toll just past the 10,000 mark, and they describe an outbreak driven by a virus the world has few tools against.
The pathogen is the Bundibugyo virus. There is no approved vaccine for it and no specific treatment. The Africa Centres for Disease Control and Prevention has called this the fastest-growing Ebola outbreak in history.
The virus has not stayed inside Congo's borders. Kenya has confirmed nine infections, including two deaths, after a patient traveled from Congo through Uganda to the capital, Nairobi. Nigeria has confirmed an infection in a Swiss woman, the wife of a Swiss diplomat, who fell ill after visiting Uganda. Authorities are still investigating where she contracted the virus. She was evacuated to Switzerland.
Several features make the disease hard to contain. Ebola spreads through direct contact with the blood or other bodily fluids of an infected person. It can cause fever, diarrhea and, in some cases, bleeding. Its early symptoms can look like malaria, which risks delaying isolation and treatment of patients who are already infectious. Without an approved vaccine or a specific drug for this strain, responders lack the usual means of protecting contacts or treating the sick.
Research is under way, though. Clinical trials of two antiviral treatment approaches have been running since July. Two further trials are testing whether the Ervebo vaccine can protect against Bundibugyo. Ervebo is currently approved and recommended only against Ebola virus, formerly known as Zaire ebolavirus, a different species from the one now spreading.
What to watch next is the output of those four trials: whether either antiviral approach shows benefit, and whether Ervebo offers any cross-protection against Bundibugyo. Alongside them, the course of the cases in Kenya and the investigation into the Swiss woman's infection will show how far the outbreak is moving beyond Congo.
Notable Quotes
It is the fastest-growing Ebola outbreak in history.— Africa Centres for Disease Control and Prevention (paraphrased)
Want the full story?
Read the original at Deutsche Welle ↗
Health & Medicine